Market Intelligence, Clinical Progress, and High-Purity Reagents for Congenital Muscular Dystrophy and Extracellular Matrix R&D.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LAMA2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LAMA2 Recombinant Protein (HEK293, His-tag) High purity (>95%), Endotoxin Controlled, Sequence Verified. Suitable for binding assays. |
View LAMA2 Products |
| Gene Delivery | LAMA2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and expression validation. |
View LAMA2 Products |
| Benchmark Ab | Anti-LAMA2 Recombinant Antibody Recombinant positive control for ELISA, Western Blot, and IHC. |
View LAMA2 Products |
| Validator | LAMA2 siRNA Set Target-specific knockdown verification in primary muscle cells. |
View LAMA2 Products |
| Related Target A | LAMA1 Upregulation of LAMA1 acts as a functional compensator for LAMA2 deficiency in MDC1A. |
View LAMA1 Products |
| Related Target B | DAG1 (Dystroglycan) Primary cell-surface receptor for LAMA2; crucial for basement membrane assembly. |
View DAG1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large protein size and complex folding | Domain-specific recombinant fragments (LN or LG domains) expressed in HEK293 to ensure native glycosylation and folding. |
| Cross-species reactivity verification | Human and Mouse LAMA2 ortholog proteins available with >95% purity by SDS-PAGE. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA included for specificity and knockdown verification. |
Live LAMA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for LAMA2-related congenital muscular dystrophy (LAMA2-CMD) is transitioning from symptomatic management to disease-modifying genetic and protein therapies. As first-generation linker therapies and gene correction technologies enter early-phase evaluation, the next wave of R&D is focusing on dual-acting laminin matrix stabilizers and compensatory gene upregulators (such as LAMA1 modifiers).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / CRISPR | Astellas Gene Therapies, ProSkelia | LAMA2-CMD (MDC1A) | Expression verification (Need LAMA2 Lentivirus / qPCR standards) |
| Protein Replacement | Santhera Pharmaceuticals | Merosin-deficient CMD | Receptor binding assays (Need high-purity LAMA2 and DAG1/Integrin proteins) |
| Linker Proteins / Abs | Academic Spin-offs | Muscular Dystrophy | Basement membrane assembly validation (Need sequence-verified antigens) |